The Association Of Fludarabin, Oral Busulfan And Thymoglobulin Prior To Matched Related Allo-SCT Allows For High Long Term Outcome For Both Patients With Myeloid Or Lymphoid Malignancies: Long Term Analysis Of A Homogenous Cohort Of 100 Consecutive Patients
Laure Farnault(Aix-Marseille Université), Didier Blaise(Institut Paoli-Calmettes), Luca Castagna(Humanitas University), Réda Bouabdallah(Institut Paoli-Calmettes), C. Lemarie(Institut Paoli-Calmettes), Jean El Cheikh(Institut Pprime), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Christian Chabannon(Inserm), Benjamin Esterni(Centre Hospitalier Universitaire de Grenoble), Boris Calmels(Institut Paoli-Calmettes), A.-M. Stoppa(Institut Paoli-Calmettes), S. Fürst(Institut Paoli-Calmettes), Patrick Ladaique(Institut Paoli-Calmettes), Catherine Faucher(Institut Paoli-Calmettes), Mohamad Mohty(Sorbonne Université)
Cited by 0
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Outcome of Treatment in Adults With Acute Lymphoblastic Leukemia: Analysis of the LALA-94 Trial
|Journal of Clinical Oncology|2004|547
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534